Acanto Prima

Primær information

  • Handelsnavn:
  • Acanto Prima Vanddispergerbart granulat
  • Lægemiddelform:
  • Vanddispergerbart granulat
  • Sammensætning:
  • 80 g/kg picoxystrobin; 300 g/kg cyprodinil
  • Brugt til:
  • Planter
  • Medicin typen:
  • agrokemiske

Dokumenter

Lokation

  • Fås i:
  • Acanto Prima Vanddispergerbart granulat
    Danmark
  • Sprog:
  • dansk

Andre oplysninger

Status

  • Kilde:
  • SEGES Landbrug & Fødevarer
  • Autorisation status:
  • Udgået
  • Autorisationsnummer:
  • Må ikke anvendes nærmere end 10 meter fra vandmiljøet (søer og vandløb m.m.).
  • Sidste ændring:
  • 23-07-2018

Indlægsseddel

www.syngenta.dk

BRUGSANVISNING

Acanto

®

Prima

Acanto

®

Prima er et bredtvirkende svampemiddel mod sygdomme i byg, hvede, rug, triticale og

havre.

01 Produktdata

Aktivstof Picoxystrobin 80 g/kg + Cyprodinil 300 g/kg

Fareklasse

Miljøfarlig

Emballage

5 kg

Opbevaring

Tørt og frostfrit, tåler dog kortvarig

frost (ned til -10

C i 14 dage)

02 Godkendt anvendelse

Acanto

Prima må kun anvendes til svampebekæmpelse i byg,

hvede, rug, triticale og havre.

03 Behandlingsfrister og restriktioner

Følgende interval mellem sprøjtning og høst skal overholdes:

42 dage

Hvede, rug, triticale og havre

2 måneder

Må ikke anvendes nærmere end 10 meter fra vandmiljøet (vand-

løb og søer m.v.).

04 Virkemåde og virkningsspektrum

Begge aktivstoffer virker systemisk i planten og har desuden en

bladgennemtrængende (translaminar) effekt. Aktivstofferne har

primært en forebyggende effekt, men picoxystrobin har også

nogen kurativ effekt på svampesygdomme. Acanto

Prima be-

kæmper

svampesygdomme

mest

effektivt

inden

svampen

etablerer sig på planten, derfor skal midlet udbringes så snart de

første sygdomstegn kan ses eller ved risiko for forestående

angreb. Kornet vil være beskyttet mod svampeangreb de næste

3-6 uger afhængig af vækststadie, væksthastighed, sygdoms-

angreb og dosering. Acanto® Prima er yderst skånsom overfor

afgrøden, hvilket sammen med god sygdomsbekæmpelse, god

langtidseffekt og forgrønnende effekt, giver høje udbytter af god

kvalitet.

Acanto

Prima virker mod følgende svampesygdomme:

Byg

Bygmeldug, bygbladplet, bygrust, skoldplet.

Hvede

Hvedebladplet, hvedebrunplet og brunrust.

Moderat effekt: Gulrust, hvedemeldug og

knækkefodsyge.

Rug og triticale Meldug, skoldplet, brunrust. Moderat effekt

knækkefodsyge.

Havre

Meldug, havrebladplet, kronrust.

Resistens:

Acanto

Prima indeholder de to aktivstoffer picoxystrobin og

cyprodinil med forskellig virkningsmekanisme. Der er ikke

fundet krydsresistens og i de tilfælde hvor begge aktivstoffer er

effektive overfor sygdommen er Acanto

Prima velegnet i en

resistensstrategi.

For at undgå udbredning af resistens er det vigtigt at følge de

angivne retningslinier for anvendelse af strobiluriner i korn.

1. Anvend maksimalt to sprøjtninger med Acanto

Prima eller

andre strobilurinholdige produkter pr. sæson. I byg dog kun en

gang.

2. Anvend Acanto

Prima forebyggende eller så tidligt som

muligt i infektionsforløbet

3. Bland Acanto

Prima med triazoler i hvede ved bekæmpelse

af hvedegråplet og hvedebrunplet

4. Anvend doseringer, både af Acanto

Prima og blandingspart-

ner, der giver en effektiv bekæmpelse.

05 Afgrøder, dosering og sprøjtetidspunkt

Sprøjtning

udføres

straks,

når

første

symptomer

svampeangreb konstateres, eller når der er udsigt til forestående

angreb afhængig af klima og sortsforhold. Acanto® Prima kan

anvendes fra kornets buskningsstadie og indtil efter skridning

(senest i BBCH 61 i alle kornarter)

Højeste dosis anvendes ved stort smittetryk i modtagelige sorter

og/eller ved ugunstige sprøjteforhold.

Afgrøde

Dosering Bemærkninger

Vårbyg

BBCH 31-61

0,5-1,5 kg/ha En sprøjtning er normalt tilstrækkelig

i vårbyg. Optimalt tidspunkt er ved

begyndende angreb oftest

BBCH 32-45.

Max dosering 1,5 kg/ha pr. sæson.

Vinterbyg

BBCH 31-61

0,5-1,5 kg/ha En sprøjtning er normalt tilstrækkelig

i vinterbyg. Optimalt tidspunkt er ved

begyndende angreb oftest

BBCH 32-45.

Max dosering 1,5 kg/ha pr. sæson.

Hvede

BBCH 31-32

0,75-1,5 kg/ha Mod knækkefodsyge anvendes

højeste dosering.

BBCH 37-61

0,75-1,5 kg/ha Ved angreb af hvedegråplet blandes

med et effektivt triazol.

Max dosering 1,5 kg/ha pr. sæson.

Rug og triticale

BBCH 31-32

0,75-1,5 kg/ha Mod knækkefodsyge anvendes

højeste dosering.

BBCH 37-65

0,75-1,5 kg/ha En sprøjtning er normalt tilstrækkelig

i rug.

Max dosering 1,5 kg/ha pr. sæson.

Havre

BBCH 31-61

0,5-1,5 kg/ha En sprøjtning er normalt tilstrækkelig

i havre. Optimalt tidspunkt er ved

begyndende angreb oftest

BBCH 32-45.

2006–01 Brugsanvisning • Acanto Prima •• side 1 (2)

Syngenta Crop Protection A/S, Strandlodsvej 44, 2300 København S

Tel 32 87 11 00, Fax 32 87 11 99, E-mail: dk.syngenta@syngenta.com

www.syngenta.dk

2006–01 Brugsanvisning

• Acanto Prima

•• side 2 (2)

Max dosering 1,5 kg/ha pr. sæson.

06 Sprøjteteknik, rengøring m.m.

Det anbefales at bruge 100-200 l vand pr. ha. Højeste vand-

mængde i tætte afgrøder hvor der er risiko for afdrift til søer og

vandløb, bør der anvendes “low drift” dyser.

Tilberedning af sprøjtevæske

Fyld tanken halvt med vand, tilsæt Acanto

Prima under om-

røring. Omrør under udsprøjtning som bør afsluttes få timer

efter blanding. Sprøjtevæske bør ikke henstå i sprøjten i længere

tid.

Forslag til sprøjteteknik (normale forhold):

Dyse

Vand (l/ha)

Tryk (bar)

Hastighed (km/t)

ISO F 02

ISO F 03

Forslag til sprøjteteknik ved risiko for afdrift ("Low drift"):

Dyse

Vand (l/ha)

Tryk (bar)

Hastighed (km/t)

ISO F 02

ISO F 03

Forslag til sprøjteteknik ved risiko for afdrift (“Hardi

Twin”):

Dyse

Vand (l/ha)

Tryk (bar)

Hastighed (km/t)

ISO F 01

ISO F 025

ISO F 03

Rengøring af sprøjteudstyr

Rengør sprøjten grundigt udvendigt og indvendigt umiddelbart

efter brug.

HUSK, at skyllevandet ikke må komme i kontakt med brønde, dræn

eller kloakker. Findes der ikke en egnet vaskeplads med fast under-

lag, opsamling og afledning (til gyllebeholder) rengøres sprøjten

bedst i marken.

TANKSPULEDYSE MONTERET

Husk at tømme sprøjten helt mellem hver skylning/vask, aktivér

alle haner/ventiler, hæv trykket så meget, at overtryksventilen fra

det selvrensende filter udløses.

1) Sprøjten tømmes helt for sprøjtevæske i marken.

2) Straks efter sprøjtning skylles sprøjten grundigt med rent

vand - både indvendigt og udvendigt. Tøm tanken ved at sprøjte

skyllevandet ud gennem bom/dyser. Skyllevandet kan sprøjtes

ud over den afgrøde, der lige er behandlet.

3) Fyld tanken med 10-15% af tankkapaciteten (100 - 200 l /

1000 l tank), tilsæt 0,5 l All Clear Extra pr. 100 l vand. Sprøjt

lidt af vaskevandet ud gennem bom/dyser, så disse sættes i blød.

Lad omrøringen og tankspuledyse køre i mindst 15 minutter,

inden indholdet tømmes ud gennem bom/dyser. Vaskevandet

kan sprøjtes ud over den afgrøde, der lige er behandlet.

HUSK: Det er altid bedre at skylle flere gange med en mindre

mængde skyllevand, end få gange med en større mængde

skyllevand.

4) Dyser og sier afmonteres og renses med samme vaskeblan-

ding.

5) Skyl tanken grundigt i 5 min. med rent vand. Skyllevandet

sprøjtes ud gennem bom/dyser.

Ved brug af tankspuledyse og rentvandstank klares punkt 2)

også ude i marken. Hvis man har tilstrækkeligt rent vand, kan

punkt 3) også startes i marken og omrøringen fortsættes, mens

man kører hjem.

INGEN TANKSPULEDYSE MONTERET

I stedet for at anvende 10 - 15% af tankkapaciteten under punkt

3) (vaskningen), skal tanken fyldes helt.

07 Optimale virkningsforhold

Svampeudvikling: Acanto

Prima skal anvendes tidligt, mens

symptomerne på angreb er svage.

Afgrøden: I god vækst og ikke hæmmet af tørke eller tidligere

sprøjtninger. Langtidseffekten afhænger udover af doserings-

størrelsen og sygdomstrykket også af afgrødens udvikling.

Regnfasthed: Acanto

Prima er regnfast efter 2 timer.

Temperatur: Acanto

Prima kan anvendes, når dagtemperatu-

ren er over 8-10 grader. Virkningen af produktet er i øvrigt ikke

særlig temperatur afhængig.

08 Tankblanding

Alle nedennævnte produkter kan anvendes i tankblanding med

Acanto

Prima under forudsætning af at brugstidspunktet for

begge produkter er sammenfaldende. Uanset hvilken blandings-

partner der anvendes er det vigtigt at begge etiketforskrifter

omkring sprøjtefrister m.m. overholdes. Bland aldrig Acanto

Prima med mere end et produkt, herunder indbefattet anven-

delse af spredemidler.

Midler mod en- og tokimbladet ukrudt

MCPA

, Express

, Ally

, Harmony

Plus, Oxitril

, Starane

180, Topik

Midler til vækstregulering

Moddus

, CCC.

Midler til bladsygdomme

Tern

, Zenit

575 EC, Folicur

, Opus

, Juventus

, Bumper

Opus

Team

Midler mod insekter

Karate

, Pirimor

og Mavrik

09 Omsåning - efterfølgende afgrøder

Der er ingen restriktioner efter anvendelse af Acanto® Prima.

For mere information om produktet se vores hjemmeside

www.syngenta.dk

Registrerede varemærker:

Syngenta Group Company: Acanto

®

, Karate

®

, Moddus

®

, Pirimor

®

,Topik

®

, Zenit

®

www.dupontagro.dk

DuPont er ISO 14000 og 9000 certificeret.

DuPont Danmark ApS

Skøjtevej 26 - 2770 Kastrup

Tlf. 32 47 98 00

www.dupontagro.dk

20-9-2018

Health Canada warns consumers to not use health products containing the potentially dangerous chemical DNP

Health Canada warns consumers to not use health products containing the potentially dangerous chemical DNP

Canadians should not buy or use health products that contain 2,4-dinitrophenol, more commonly known as DNP, because it is toxic and can cause death. Products containing DNP are primarily marketed towards bodybuilders and are promoted online as a "fat burner" or "shredder" and for weight loss.

Health Canada

31-8-2018

Alcon Announces Voluntary Global Market Withdrawal of CyPass Micro-Stent for Surgical Glaucoma

Alcon Announces Voluntary Global Market Withdrawal of CyPass Micro-Stent for Surgical Glaucoma

Reflecting its uncompromising commitment to patient safety, Alcon today announced an immediate, voluntary market withdrawal of the CyPass Micro-Stent from the global market. In addition, Alcon advises surgeons to immediately cease further implantation with the CyPass Micro-Stent and to return any unused devices to Alcon. This decision and corresponding recommendation is based on an analysis of five-year post-surgery data from the COMPASS-XT long-term safety study. The US Food and Drug Administration (FD...

FDA - U.S. Food and Drug Administration

30-8-2018

Anthrax

Anthrax

Anthrax is a zoonosis (i.e. a disease common to humans and animals) that primarily affects herbivores. It is caused by Bacillus anthracis, a bacterium that is unusual in that it persists in soil for decades as spores. ANSES is the National Reference Laboratory for this disease. Here we provide a presentation of the disease and the role played by ANSES.

France - Agence Nationale du Médicament Vétérinaire

29-8-2018

Scientific Opinion on the state of the art of Toxicokinetic/Toxicodynamic (TKTD) effect models for regulatory risk assessment of pesticides for aquatic organisms

Scientific Opinion on the state of the art of Toxicokinetic/Toxicodynamic (TKTD) effect models for regulatory risk assessment of pesticides for aquatic organisms

Published on: Thu, 23 Aug 2018 00:00:00 +0200 Following a request from EFSA, the Panel on Plant Protection Products and their Residues (PPR) developed an opinion on the state of the art of Toxicokinetic/Toxicodynamic (TKTD) models and their use in prospective environmental risk assessment (ERA) for pesticides and aquatic organisms. TKTD models are species‐ and compound‐specific and can be used to predict (sub)lethal effects of pesticides under untested (time‐variable) exposure conditions. Three differen...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Risk to human and animal health related to the presence of 4,15‐diacetoxyscirpenol in food and feed

Risk to human and animal health related to the presence of 4,15‐diacetoxyscirpenol in food and feed

Published on: Thu, 16 Aug 2018 00:00:00 +0200 4,15‐Diacetoxyscirpenol (DAS) is a mycotoxin primarily produced by Fusarium fungi and occurring predominantly in cereal grains. As requested by the European Commission, the EFSA Panel on Contaminants in the Food Chain (CONTAM) assessed the risk of DAS to human and animal health related to its presence in food and feed. Very limited information was available on toxicity and on toxicokinetics in experimental and farm animals. Due to the limitations in the avai...

Europe - EFSA - European Food Safety Authority Publications

21-8-2018

Companies can now apply for authorisation to produce cannabis bulk and cannabis primary products

Companies can now apply for authorisation to produce cannabis bulk and cannabis primary products

On 1 July 2018, a new executive order entered into force which gives companies the possibility of cultivating medicinal cannabis and producing cannabis bulk and cannabis primary products from Danish-grown cannabis.

Danish Medicines Agency

24-7-2018

FDA Advises Vets of Percorten™-V Shortage and Alternative Drug Option for Treatment of Canine Addison’s Disease

FDA Advises Vets of Percorten™-V Shortage and Alternative Drug Option for Treatment of Canine Addison’s Disease

FDA is aware of a shortage of Percorten™-V (desoxycorticosterone pivalate injectable suspension), which is approved for use as replacement therapy for mineralocorticoid deficit in dogs with primary adrenocortical insufficiency, more commonly known as Addison’s Disease.

FDA - U.S. Food and Drug Administration

13-7-2018

Scientific guideline:  Guideline on good pharmacogenomic practice - First version, adopted

Scientific guideline: Guideline on good pharmacogenomic practice - First version, adopted

This guideline provides recommendations for the conduct of genomic studies in relation to medical therapy in order to provide high quality information on the impact of genomic variability on drug response. Primary focus is on the analysis of genomic germline DNA. The analysis of somatic DNA and genomic biomarkers for cancer treatment is not being discussed and might be developed as an Annex or in separate guidance.

Europe - EFSA - European Food Safety Authority EFSA Journal

21-6-2018

Now Health Group Inc. Recalls Select Now Real Food® Zesty Sprouting Mix Because of Possible Health Risk

Now Health Group Inc. Recalls Select Now Real Food® Zesty Sprouting Mix Because of Possible Health Risk

NOW Health Group, Inc. (NOW), of Bloomingdale, Illinois, is recalling its NOW Real Food® Zesty Sprouting Mix – Product Code 7271, Lot #3031259 and Lot #3038165 – because its primary ingredient, Crimson Clover Seeds, has the potential to be contaminated with Salmonella, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Healthy persons infected with Salmonella often experience fever, diarrhea (which may b...

FDA - U.S. Food and Drug Administration

10-8-2017

Bravecto® may cause convulsions in dogs on rare occasions

Bravecto® may cause convulsions in dogs on rare occasions

The European Medicines Agency has reviewed the adverse events of Bravecto®, a veterinary medicine used to treat flea and tick infestations in dogs. The conclusion is that the medicine may on very rare occasions cause convulsions in dogs – primarily in dogs with pre-existing epilepsy.

Danish Medicines Agency

16-6-2017

Eleven new substances on the list of euphoriant substances

Eleven new substances on the list of euphoriant substances

On 15 June 2017, 11 new substances were included in annex 1 of executive order no. 557 of 31 May 2011 on euphoriant substances issued by the Danish Ministry of Health. The information is primarily relevant to companies authorised to deal with euphoriant substances.

Danish Medicines Agency

30-11-2016

Twelve new substances on the list of euphoriant substances

Twelve new substances on the list of euphoriant substances

As of 24 November 2016, 12 new substances are included in the Danish executive order no. 557 of 31 May 2011 on euphoriant substances issued by the Danish Ministry of Health. The information is primarily relevant to companies authorised to deal with euphoriant substances.

Danish Medicines Agency

12-6-2015

CUG certificates for login to DKMAnet must be replaced

CUG certificates for login to DKMAnet must be replaced

The Danish Health and Medicines Authority has to replace the system used to issue Closed User Group (CUG) certificates to users of DKMAnet who cannot obtain a NemID employee certificate, i.e. primarily users employed in companies without a Danish CVR registration number. If you are currently using a CUG certificate of the old type to log in to DKMAnet, you must obtain a new certificate before 1 September 2015.

Danish Medicines Agency

13-9-2018

 European Medicines Agency stakeholder interaction on the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH), European Medicines Agency, London, UK, From: 03-Dec-2018, To: 03-Dec-2018

European Medicines Agency stakeholder interaction on the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH), European Medicines Agency, London, UK, From: 03-Dec-2018, To: 03-Dec-2018

This workshop on the development of medicines for chronic non-infectious liver diseases, including primary biliary cholangitis, primary sclerosing cholangitis and nonalcoholic steatohepatitis, provides a platform for discussion on appropriate endpoints including validation of surrogate endpoints/biomarkers, suitable study populations, potentially adequate trial designs and the specific challenges with paediatric medicine development. The workshop will support the drafting of a reflection paper on regul...

Europe - EMA - European Medicines Agency

7-9-2018

Newsletter:  Human medicines highlights - September 2018

Newsletter: Human medicines highlights - September 2018

This newsletter is addressed primarily to organisations representing patients, consumers and healthcare professionals. It provides a summary of key information relating to medicines for human use published during the previous month by the European Medicines Agency.

Europe - EMA - European Medicines Agency

21-8-2018

Do you wear contact lenses? This rare but serious infection of the eye primarily affects people who wear contact lenses. #GuessthePathogen, and make sure to practice healthy habits  http://bit.ly/2ifnt2O  #ContactLensHealthWeekpic.twitter.com/ZBZAAtbrVr

Do you wear contact lenses? This rare but serious infection of the eye primarily affects people who wear contact lenses. #GuessthePathogen, and make sure to practice healthy habits http://bit.ly/2ifnt2O  #ContactLensHealthWeekpic.twitter.com/ZBZAAtbrVr

Do you wear contact lenses? This rare but serious infection of the eye primarily affects people who wear contact lenses. #GuessthePathogen, and make sure to practice healthy habits http://bit.ly/2ifnt2O  #ContactLensHealthWeek pic.twitter.com/ZBZAAtbrVr

FDA - U.S. Food and Drug Administration

6-8-2018

Human medicines highlights - August 2018

Human medicines highlights - August 2018

This newsletter is addressed primarily to organisations representing patients, consumers and healthcare professionals. It provides a summary of key information relating to medicines for human use published during the previous month by the European Medicines Agency.

Europe - EMA - European Medicines Agency

10-7-2018

Human medicines highlights - July 2018

Human medicines highlights - July 2018

This newsletter is addressed primarily to organisations representing patients, consumers and healthcare professionals. It provides a summary of key information relating to medicines for human use published during the previous month by the European Medicines Agency.

Europe - EMA - European Medicines Agency

8-5-2018

Human medicines highlights - June 2018

Human medicines highlights - June 2018

This newsletter is addressed primarily to organisations representing patients, consumers and healthcare professionals. It provides a summary of key information relating to medicines for human use published during the previous month by the European Medicines Agency.

Europe - EMA - European Medicines Agency

9-4-2018

Human medicines highlights - April 2018

Human medicines highlights - April 2018

This newsletter is addressed primarily to organisations representing patients, consumers and healthcare professionals. It provides a summary of key information relating to medicines for human use published during the previous month by the European Medicines Agency.

Europe - EMA - European Medicines Agency

9-3-2018

Human medicines highlights - March 2018

Human medicines highlights - March 2018

This newsletter is addressed primarily to organisations representing patients, consumers and healthcare professionals. It provides a summary of key information relating to medicines for human use published during the previous month by the European Medicines Agency.

Europe - EMA - European Medicines Agency

8-2-2018

Human medicines highlights - February 2018

Human medicines highlights - February 2018

This newsletter is addressed primarily to organisations representing patients, consumers and healthcare professionals. It provides a summary of key information relating to medicines for human use published during the previous month by the European Medicines Agency.

Europe - EMA - European Medicines Agency

5-1-2018

Human medicines highlights - January 2018

Human medicines highlights - January 2018

This newsletter is addressed primarily to organisations representing patients, consumers and healthcare professionals. It provides a summary of key information relating to medicines for human use published during the previous month by the European Medicines Agency.

Europe - EMA - European Medicines Agency

6-12-2017

Human medicines highlights - December 2017

Human medicines highlights - December 2017

This newsletter is addressed primarily to organisations representing patients, consumers and healthcare professionals. It provides a summary of key information relating to medicines for human use published during the previous month by the European Medicines Agency.

Europe - EMA - European Medicines Agency

8-11-2017

Human medicines highlights - November 2017

Human medicines highlights - November 2017

This newsletter is addressed primarily to organisations representing patients, consumers and healthcare professionals. It provides a summary of key information relating to medicines for human use published during the previous month by the European Medicines Agency.

Europe - EMA - European Medicines Agency